我们旨在评估临床实践中脑转移患者特征和治疗的近期趋势。所有在单个癌症中心被诊断患有脑转移的新患者在2016年至2021年之间被纳入研究。我们收集每个患者的详细特征，并估计符合以下用于常见临床试验的标准的候选人数量：Karnofsky绩效状态≥70和突变的非小细胞肺癌、乳腺癌或黑色素瘤。脑转移治疗被分类为：（i）立体定向放射外科、（ii）立体定向放射外科和全身治疗、（iii）整脑放疗、（iv）整脑放疗和全身治疗、（v）手术、（vi）免疫检查点抑制剂或靶向治疗、（vii）细胞毒性药物和（IX）姑息治疗。从脑转移诊断到死亡或颅内进展，估计总生存和颅内无进展生存。共分析了800名脑转移患者； 其中597名（74.6％）接受放射治疗，422名（52.7％）接受全身治疗。此外，250名（31.3％）患者被认为符合常见临床试验的标准。与2016年相比，后几年的治疗选择从整脑放疗向立体定向放射外科转移（整脑放疗：35.7-29.1％，立体定向放射外科：33.4-42.8％），从细胞毒性药物转为免疫检查点抑制剂/靶向治疗（细胞毒性药物：10.1-5.0，免疫检查点抑制剂/靶向治疗：7.8-10.9％）。联合放射治疗的全身治疗比例也有所增加（从26.4％增加到36.5％）。中位总生存和无进展生存分别为12.7个月和5.3个月。 该研究揭示了脑转移患者特征的多样性，治疗选择的最新变化以及临床试验中候选人的比例。©作者（们）2023年。牛津大学出版社保留所有权利。有关权限，请发送电子邮件至：journals.permission@oup.com。

We aimed to evaluate recent trends in characteristics and treatments among patients with brain metastases in clinical practice.All newly diagnosed patients with brain metastases during 2016-2021 at a single cancer center were enrolled. We collected the detailed features of each patient and estimated the number of candidates considered to meet the following criteria used in common clinical trials: Karnofsky performance status ≥ 70 and mutated non-small cell lung cancer, breast cancer or melanoma. The brain metastases treatments were classified as follows: (i) stereotactic radiosurgery, (ii) stereotactic radiosurgery and systemic therapy, (iii) whole-brain radiotherapy, (iv) whole-brain radiotherapy and systemic therapy, (v) surgery, (vi) immune checkpoint inhibitor or targeted therapy, (vii) cytotoxic agents and (ix) palliative care. Overall survival and intracranial progression-free survival were estimated from brain metastases diagnosis to death or intracranial progression.A total of 800 brain metastases patients were analyzed; 597 (74.6%) underwent radiotherapy, and 422 (52.7%) underwent systemic therapy. In addition, 250 (31.3%) patients were considered candidates for common clinical trials. Compared to 2016, the later years tended to shift from whole-brain radiotherapy to stereotactic radiosurgery (whole-brain radiotherapy: 35.7-29.1% and stereotactic radiosurgery: 33.4-42.8%) and from cytotoxic agents to immune checkpoint inhibitor/targeted therapy (cytotoxic agents: 10.1-5.0 and immune checkpoint inhibitor/targeted therapy: 7.8-10.9%). There was also an increase in the proportion of systemic therapy combined with radiation therapy (from 26.4 to 36.5%). The median overall survival and progression-free survival were 12.7 and 5.3 months, respectively.This study revealed the diversity of brain metastases patient characteristics, recent changes in treatment selection and the percentage of candidates in clinical trials.© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.